Enanta Pharma (ENTA) Tops Q2 EPS by 10c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $8.96 million versus the consensus estimate of $9.19 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)